JO2178B1 - Treatment of emphysema using rar selective retinoid antagonists - Google Patents

Treatment of emphysema using rar selective retinoid antagonists

Info

Publication number
JO2178B1
JO2178B1 JO2000172A JOP20000172A JO2178B1 JO 2178 B1 JO2178 B1 JO 2178B1 JO 2000172 A JO2000172 A JO 2000172A JO P20000172 A JOP20000172 A JO P20000172A JO 2178 B1 JO2178 B1 JO 2178B1
Authority
JO
Jordan
Prior art keywords
treatment
rar
antigens
selected anti
invasive diseases
Prior art date
Application number
JO2000172A
Other languages
Arabic (ar)
English (en)
Inventor
نايت بيلوني بولا
كلوز ميشيل
Original Assignee
اف . هوفمان لاروش ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اف . هوفمان لاروش ايه جي filed Critical اف . هوفمان لاروش ايه جي
Application granted granted Critical
Publication of JO2178B1 publication Critical patent/JO2178B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JO2000172A 1999-10-19 2000-10-12 Treatment of emphysema using rar selective retinoid antagonists JO2178B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19

Publications (1)

Publication Number Publication Date
JO2178B1 true JO2178B1 (en) 2003-04-23

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2000172A JO2178B1 (en) 1999-10-19 2000-10-12 Treatment of emphysema using rar selective retinoid antagonists

Country Status (33)

Country Link
US (1) US6300350B1 (https=)
EP (1) EP1225878B1 (https=)
JP (2) JP4074458B2 (https=)
KR (1) KR100485581B1 (https=)
CN (1) CN1201730C (https=)
AR (1) AR029648A1 (https=)
AT (1) ATE344661T1 (https=)
AU (1) AU777325B2 (https=)
BR (1) BR0015225A (https=)
CA (1) CA2387844C (https=)
CY (1) CY1105941T1 (https=)
CZ (1) CZ20021657A3 (https=)
DE (1) DE60031790T2 (https=)
DK (1) DK1225878T3 (https=)
ES (1) ES2274810T3 (https=)
HR (1) HRP20020329A2 (https=)
HU (1) HUP0203295A3 (https=)
IL (1) IL149151A0 (https=)
JO (1) JO2178B1 (https=)
MA (1) MA26835A1 (https=)
MX (1) MXPA02003843A (https=)
MY (1) MY129001A (https=)
NO (1) NO328738B1 (https=)
NZ (1) NZ518118A (https=)
PE (1) PE20010678A1 (https=)
PL (1) PL357499A1 (https=)
PT (1) PT1225878E (https=)
RS (1) RS50165B (https=)
RU (1) RU2257383C2 (https=)
TR (1) TR200201071T2 (https=)
TW (1) TWI288639B (https=)
WO (1) WO2001030326A1 (https=)
ZA (1) ZA200202576B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
BR0212583A (pt) * 2001-09-18 2004-10-13 Hoffmann La Roche Agonistas i para retinóides de alquil uréia
EP1430023B1 (en) 2001-09-18 2009-04-08 F. Hoffmann-La Roche Ag Substituied urea retinoid agonists ii
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
ES2481167T3 (es) 2003-08-22 2014-07-29 Dupont Nutrition Biosciences Aps Composición que comprende una bacteriocina y un extracto de una planta de la familia Labiatae
US20100076037A1 (en) * 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
EP3721880B1 (en) 2010-09-01 2022-02-02 Thomas Jefferson University Composition and method for muscle repair and regeneration
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US20140155381A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
SG10201708931XA (en) 2012-12-17 2017-12-28 Parion Sciences Inc Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
WO2015026990A2 (en) 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase
US10500232B2 (en) 2013-08-26 2019-12-10 The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0139216B1 (ko) * 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
ES2212797T3 (es) * 1993-08-19 2004-08-01 Janssen Pharmaceutica N.V. Derivados de dihidrobenzopirano vasoconstrictores.
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
DK0728742T3 (da) * 1995-02-24 2000-04-17 Hoffmann La Roche Hidtil ukendte retinoider
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) * 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
EP1030662B1 (en) * 1997-11-12 2006-08-02 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
AU4222400A (en) 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
MXPA02000828A (es) * 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
NO328738B1 (no) 2010-05-03
MA26835A1 (fr) 2004-12-20
KR100485581B1 (ko) 2005-04-27
HK1051002A1 (en) 2003-07-18
TR200201071T2 (tr) 2002-08-21
RS50165B (sr) 2009-05-06
ES2274810T3 (es) 2007-06-01
PT1225878E (pt) 2007-01-31
YU29002A (sh) 2005-06-10
ATE344661T1 (de) 2006-11-15
HRP20020329A2 (en) 2004-04-30
TWI288639B (en) 2007-10-21
HUP0203295A3 (en) 2003-04-28
KR20020043640A (ko) 2002-06-10
AU1137401A (en) 2001-05-08
DE60031790D1 (de) 2006-12-21
PE20010678A1 (es) 2001-07-04
IL149151A0 (en) 2002-11-10
MY129001A (en) 2007-03-30
HUP0203295A2 (hu) 2003-01-28
CN1201730C (zh) 2005-05-18
MXPA02003843A (es) 2002-09-30
US6300350B1 (en) 2001-10-09
EP1225878A1 (en) 2002-07-31
JP4074458B2 (ja) 2008-04-09
NO20021823D0 (no) 2002-04-18
EP1225878B1 (en) 2006-11-08
CZ20021657A3 (cs) 2002-10-16
JP2007302689A (ja) 2007-11-22
PL357499A1 (pl) 2004-07-26
BR0015225A (pt) 2002-07-16
JP2003512418A (ja) 2003-04-02
ZA200202576B (en) 2003-09-23
NZ518118A (en) 2004-02-27
CA2387844C (en) 2009-04-14
CN1382042A (zh) 2002-11-27
RU2257383C2 (ru) 2005-07-27
JP4850791B2 (ja) 2012-01-11
NO20021823L (no) 2002-04-18
AU777325B2 (en) 2004-10-14
DK1225878T3 (da) 2007-03-05
AR029648A1 (es) 2003-07-10
CY1105941T1 (el) 2011-04-06
CA2387844A1 (en) 2001-05-03
DE60031790T2 (de) 2007-09-20
WO2001030326A1 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
JO2178B1 (en) Treatment of emphysema using rar selective retinoid antagonists
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
CR8012A (es) Clavo endomedular destinado al tratamiento de fracturas de femur proximal
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
ATE408601T1 (de) Fredericamycin-derivate
CY1110721T1 (el) Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις
CY2013004I1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
NO20024238D0 (no) Peptidase-spaltbare, målsökende antineoplastiske medikamenter, og deres terapautiske anvendelse
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
WO2003080582A3 (de) Fredericamycin-derivate
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
AR032293A1 (es) Estuche farmaceutico
GB0222514D0 (en) Organic compounds
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
WO2005007149A8 (de) Ambroxol für die behandlung akuter schmerzen
WO2005020908A3 (en) Selective inhibitors of stat-3 activation and uses thereof
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
MXPA04001912A (es) Aminobenzofenonas novedosas.
CY1106702T1 (el) Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων